Results of the Phase I clinical trial, presented at the bi-annual Contrast Media Research symposium in Oslo, Norway, conclude that this novel macrocyclic manganese-based contrast agent was well ...

This project pioneers ‘Phase Imaging’ that visualizes the phase information of quantum beams (X-rays, neutrons, electrons, and so on) passing through objects. Phase imaging is different from ...

Among over 6,300 women who completed supplementary imaging, the cancer detection rate per 1,000 examinations was 17.4 for abbreviated MRI, 4.2 for ABUS, and 19.2 for contrast-enhanced mammography ...

Perfuse Therapeutics reveals promising Phase 2 trial results for PER-001, a potential treatment for glaucoma and diabetic ...

A new brain imaging study has found that women’s attention and cognitive control can be influenced by hormonal fluctuations ...

The investigational MRI contrast agent, gadoquatrane, is designed to deliver effective imaging at a significantly reduced ...

GE HealthCare has announced positive results from a Phase I study of its manganese-based macrocyclic magnetic resonance imaging (MRI) contrast agent. Data from the first-in-human trial ...

Barium contrast media plays an essential role in gastrointestinal imaging, offering a reliable, radiopaque medium with favorable safety and cost profiles compared to iodinated agents.

A new publication from Opto-Electronic Advances; DOI 10.29026/oea.2024.240060, discusses multi-prior intelligent microscopy assisted high-throughput, pixel super-resolution quantitative phase imaging.

Results of the Phase I clinical trial, presented at the bi-annual Contrast Media Research symposium in Oslo, Norway, conclude that this novel macrocyclic manganese-based contrast agent was well ...

Results of the Phase I clinical trial, presented at the bi-annual Contrast Media Research symposium in Oslo, Norway, conclude that this novel macrocyclic manganese-based contrast agent was well ...